CSIMarket
 


Celgene Corp  (CELG)
Other Ticker:  
 
 

CELG's Operating Income Growth by Quarter and Year

Celgene's Operating Income results by quarter and year




CELG Operating Income (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
IV Quarter December - 1,807.00 1,203.00 929.90
III Quarter September 2,264.00 1,680.00 1,085.00 411.50
II Quarter June 2,111.00 1,486.00 1,308.00 823.70
I Quarter March 1,710.00 218.00 1,111.00 1,001.50
FY   6,085.00 5,191.00 4,707.00 3,166.60



CELG Operating Income third quarter 2019 Y/Y Growth Comment
Celgene Corp reported Operating Income improvement of 34.76% year on year in the third quarter 2019, to $ 2,264.00 millions, this is lower than Celgene Corp's recent average Operating Income rise of 73.99%.

Looking into third quarter 2019 results within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Operating Income growth. While Celgene Corp' s Operating Income rise of 34.76% ranks overall at the positon no. 536 in the third quarter 2019.

Explain Operating Income growth


CELG Operating Income ( Y/Y Growth %) 2019
2018 2017 2016
IV Quarter December - 50.21 % 29.37 % 3.3 %
III Quarter September 34.76 % 54.84 % 163.67 % 416.96 %
II Quarter June 42.06 % 13.61 % 58.8 % 98.1 %
I Quarter March 684.4 % -80.38 % 10.93 % 16.59 %
FY   - 10.28 % 48.65 % 40.45 %

Financial Statements
Celgene's third quarter 2019 Operating Income $ 2,264.00 millions CELG's Income Statement
Celgene's third quarter 2018 Operating Income $ 1,680.00 millions Quarterly CELG's Income Statement
New: More CELG's historic Operating Income Growth >>


CELG Operating Income (Quarter on Quarter Growth %)

2019
2018 2017 2016
IV Quarter December - 7.56 % 10.88 % 125.98 %
III Quarter September 7.25 % 13.06 % -17.05 % -50.04 %
II Quarter June 23.45 % 581.65 % 17.73 % -17.75 %
I Quarter March -5.37 % -81.88 % 19.48 % 11.25 %
FY (Year on Year)   - 10.28 % 48.65 % 40.45 %




Operating Income third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #48
Overall #536

Operating Income Y/Y Growth Statistics
High Average Low
684.4 % 73.99 % -87.69 %
(Mar 31 2019)   (Sep 30 2015)
Operating Income third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #48
Overall #536
Operating Income Y/Y Growth Statistics
High Average Low
684.4 % 73.99 % -87.69 %
(Mar 31 2019)   (Sep 30 2015)

Operating Income by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Celgene's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
1030.9 % 42.04 % -81.88 %
(Dec 31 2015)  


CELG's III. Quarter Q/Q Operating Income Comment
Celgene Corp achieved in the III. Quarter 2019 below company average Operating Income increase of 7.25% quarter on quarter, to $ 2,264.00 millions.

Within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Operating Income quarter on quarter growth. While Celgene's Operating Income growth quarter on quarter, overall rank is 1041.


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #70
Overall #1041
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #70
Overall #1041
Operating Income Q/Q Growth Statistics
High Average Low
1030.9 % 42.04 % -81.88 %
(Dec 31 2015)  


CELG's III. Quarter Q/Q Operating Income Comment
Celgene Corp achieved in the III. Quarter 2019 below company average Operating Income increase of 7.25% quarter on quarter, to $ 2,264.00 millions.

Within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Operating Income quarter on quarter growth. While Celgene's Operating Income growth quarter on quarter, overall rank is 1041.


Celgene's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Mar 31 2019)
12 Months Ending
(Dec 31 2018)
12 Months Ending
(Sep 30 2018)
Cumulative Operating Income 12 Months Ending $ 7,892.00 $ 7,308.00 $ 6,683.00 $ 5,191.00 $ 4,587.00
Y / Y Operating Income Growth (TTM) 72.05 % 83.07 % 75.22 % 10.28 % 3.45 %
Year on Year Operating Income Growth Overall Ranking # 298 # 282 # 287 # 857 # 1268
Seqeuential Operating Income Change (TTM) 7.99 % 9.35 % 28.74 % 13.17 % 14.9 %
Seq. Operating Income Growth (TTM) Overall Ranking # 829 # 674 # 196 # 451 # 676




Cumulative Operating Income growth Comment
Assuming the Celgene's fiscal year would have ended in Sep 30 2019, Celgene would have reprted above average annual Operating Income growth of 72.05% year on year, of $ 7,892 millions.
This marks a slow-down of the companys growth trends and from the 83.07% increase in Jun 30 2019.

Within the Healthcare sector 30 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 282 to 298.

Operating Income TTM Q/Q Growth Statistics
High Average Low
267.29 %
7.01 %
-662.8 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 21
Healthcare Sector # 31
Overall # 298

Operating Income TTM Y/Y Growth Statistics
High Average Low
267.29 %
51.38 %
-39.71 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 64
S&P 500 # 829
Cumulative Operating Income growth Comment
Assuming the Celgene's fiscal year would have ended in Sep 30 2019, Celgene would have reprted above average annual Operating Income growth of 72.05% year on year, of $ 7,892 millions.
This marks a slow-down of the companys growth trends and from the 83.07% increase in Jun 30 2019.

Within the Healthcare sector 30 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 282 to 298.

Operating Income TTM Q/Q Growth Statistics
High Average Low
267.29 %
7.01 %
-662.8 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 21
Healthcare Sector # 31
Overall # 298

Operating Income TTM Y/Y Growth Statistics
High Average Low
267.29 %
51.38 %
-39.71 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 64
S&P 500 # 829




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
CELG's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for CELG's Competitors
Operating Income Growth for Celgene's Suppliers
Operating Income Growth for CELG's Customers

You may also want to know
CELG's Annual Growth Rates CELG's Profitability Ratios CELG's Asset Turnover Ratio CELG's Dividend Growth
CELG's Roe CELG's Valuation Ratios CELG's Financial Strength Ratios CELG's Dividend Payout Ratio
CELG's Roa CELG's Inventory Turnover Ratio CELG's Growth Rates CELG's Dividend Comparisons



Companies with similar Operating Income increase for the quarter ending Sep 30 2019 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2019
Protokinetix Incorporated59.19%$ 59.193 millions
Bio rad Laboratories Inc 58.40%$ 58.401 millions
Zomedica Corp 54.16%$ 54.165 millions
Fonar Corporation50.79%$ 50.786 millions
Msa Safety Incorporated49.02%$ 49.024 millions
Alexion Pharmaceuticals Inc 47.80%$ 47.797 millions
Tenax Therapeutics Inc 45.44%$ 45.439 millions
Corcept Therapeutics Inc43.69%$ 43.689 millions
Teleflex Incorporated43.26%$ 43.257 millions
Anika Therapeutics Inc 40.55%$ 40.546 millions
Carlisle Companies Incorporated36.43%$ 36.429 millions
Celgene Corp34.76%$ 34.762 millions
Nature s Sunshine Products inc 33.82%$ 33.817 millions
Lhc Group Inc 33.71%$ 33.710 millions
Ensign Group Inc32.98%$ 32.977 millions
Surgery Partners Inc 31.10%$ 31.102 millions
Davita Inc 30.89%$ 30.895 millions
Baxter International Inc 30.65%$ 30.649 millions
Johnson and Johnson29.51%$ 29.506 millions
Bio techne Corp29.36%$ 29.360 millions
Lemaitre Vascular Inc 28.01%$ 28.008 millions
Illumina Inc 27.80%$ 27.801 millions
Bruker Corporation27.06%$ 27.062 millions
Biospecifics Technologies Corp26.81%$ 26.806 millions
Addus Homecare Corporation23.33%$ 23.327 millions
Zoetis Inc 23.18%$ 23.179 millions
Select Medical Holdings Corp23.11%$ 23.107 millions
United Therapeutics Corporation22.59%$ 22.594 millions
Quidelortho Corp22.42%$ 22.422 millions
Abbott Laboratories20.40%$ 20.402 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com